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Overall there were substantial percentages of CDATS patients with one or more risk 
factors for liver disease, many of which are modifiable.  Over half of patients have a 
record of engaging in hazardous alcohol use, and approximately a quarter have 
injected drugs, with a similar percentage having hepatitis C.   
 
Although the percentage of clients with liver disease risk factors appeared to be 
higher based on self-reported questionnaire data, particularly for hepatitis C and 
mental health, much of this is likely to be due to the limitations of the available 
electronic medical record data. 
 
Clinical staff view the major obstacles to treatment for liver disease risk factors as low 
client prioritisation of overall health and lack of understanding about the 
consequences of viral infections and alcohol use.  Clinical support tools focused on 
improving risk communication could enhance treatment interest and uptake. 
 
However, staff also highlighted clients’ unstable living situations and poor mental 
health as obstacles to treatment for liver disease risk factors.  This is particularly 
concerning given the large percentage of patients who reported unstable living 
situations (approximately 30-40%), and mental health problems (between 10% and 
65%).  Supporting clients to organise stable housing and access mental health 
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BRC Biomedical Research Centre 
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The UK liver disease mortality rate has increased 400% since 1970, making it the third 
largest cause of premature mortality (Williams et al. 2014).  The major causes of 
advanced liver disease in the UK are alcoholic cirrhosis and chronic viral hepatitis 
(Tsochatzis et al. 2014; Edeghere et al. 2015).  People with substance use disorders 
(SUDs) have greater alcohol consumption, and hepatitis B and hepatitis C infection 
than the general population, making them important targets for liver disease 
prevention.  Over 35% of people treated for SUDs are treated for alcohol use, and at 
least 25% treated for illicit drug use also drink heavily (Public Health England 2014; 
Gossop et al. 2003).  Estimated hepatitis B and C exposure is 32% and 50.5% 
respectively in people who inject drugs (PWID) in the UK, with this group accounting 
for most new hepatitis C infections (Nelson et al. 2011; Bennett et al. 2015).  
 
Prevention and early intervention are effective in stabilising liver disease progression 
and reducing morbidity, mortality, and the need for transplantation.  Achieving 
sustained virologic response in hepatitis C treatment is associated with regression of 
liver fibrosis and cirrhosis, substantially reduced risk of hepatocellular carcinoma and 
mortality, and 13-fold lower subsequent medical costs (Tsochatzis et al. 2014; Smith-
Palmer et al. 2015).  Reduction in the use of tobacco, alcohol, and cannabis is also 
beneficial; even in non-alcoholic liver disease, moderate use of alcohol more than 
doubles the risk of cirrhosis, while tobacco and cannabis use both worsen the 
progression of fibrosis (Tsochatzis et al. 2014).  However, treatment levels for hepatitis 
B and hepatitis C infection, and secondary alcohol misuse, are low especially 
amongst SUD patients which has led to calls for tools to help clinicians identify high-
risk patients and target treatment (Staiger et al. 2013; Williams et al. 2014; Bennett et 
al. 2015; Tsochatzis et al. 2014; Smith-Palmer et al. 2015). 
 
Study Aims and Objectives 
 
The aim of this project was to characterise the current clinical landscape regarding 
detection and treatment of liver disease risk factors in individuals undergoing 
treatment for alcohol and/or drug dependence, using a combination of electronic 
medical record data and data directly collected from staff and clients.  It addressed 
the following research questions: 
 
1. What is the percentage of addiction services clients who have known risk 
factors for liver disease? 
2. How do self-reports of risk factors compare to what is included in clinical 
records? 
3. What are the attitudes of clinical staff and clients to interventions for liver 







Selection of Risk Factors for Liver Disease 
 
Risk factors for liver disease were identified from the literature and discussions with 
clinical colleagues who work with clients in treatment for drug and alcohol 
dependence.  We selected a range of individual-level risk factors, with a focus on 
relevance to treatment and potential for modification:  
 
• Sociodemographics 
o Country of birth 
o Living situation 
o Time in prison 
• Substance use 
o Hazard alcohol use 
o Illicit drug use 
• Physical health 
o Diabetes 
o Blood-borne viruses: hepatitis A, B, and C and HIV/AIDS 
• Risk behaviours 
o Injecting drugs, sharing injecting equipment, high-risk sexual behaviour 
• Mental health 
o Psychotic illnesses 
o Anxiety and depression 
 
This selection guided the focus of the information that was extracted from the 
medical record data, and the design of the client and staff surveys. 
 




The South London and Maudsley NHS Foundation Trust (SLaM) BRC Case Register was 
set up in 2008 as a novel data resource derived directly from the routine EHR data 
from a large mental healthcare provider which provides comprehensive mental 
health services to a geographic catchment of over 1.2 million residents in south 
London, as well as some regional/national specialist services.  The Case Register 
currently contains records for over 250,000 patients and includes both structured 
data and clinical notes.  Clinical records have been electronic across all SLaM 
services since April 2006, using the bespoke electronic Patient Journey System (ePJS). 
The Clinical Record Interactive Search (CRIS) application was developed to 
anonymise and structure data from ePJS, making it available for research use.  The 
Case Register and CRIS application have been described in depth in multiple 
publications (Stewart et al. 2009; Perera et al. 2016).   
 
Additionally, SLaM has established the Clinical Data Linkage Service (CDLS) as a 
trusted third party safe haven to enable safe and secure data processing services 
(linkage, and/or storage, and/or extraction) on distinct data sets for secondary 
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research use, which enables CRIS data to be linked to other external data sources 
(Stewart et al. 2009; Perera et al. 2016).  One of the available data linkages were 
relevant to this project: Hospital Episode Statistics (HES).  HES data are compiled from 
all NHS Trusts in England (both acute and mental health services), including statistical 
abstracts of records of all inpatient episodes, as well as outpatient and emergency 




The complex longitudinal nature of EHR data lends itself to the use of a range of study 
designs.  For this project, we were interested in the percentage of patients with liver 
disease risk factors at commencement of CDATS treatment.  We defined this as the 
first time an individual engaged with a SLaM CDATS within the timeframe covered by 
CRIS (from January 1st, 2007 to our census date of May 4th, 2017).   
 
However, resolving this index date is not straightforward as referral to a DATS will 
create a record in the SLaM EHR system if the patient is accepted for treatment, even 
if the patient referred does not subsequently make contact with clinical staff.  
Consequently, as the type and outcome of appointments is also recorded in case 
register, we defined the index date as the first face-to-face appointment with a 
CDATS that an accepted patient attended. 
 
Ideally, all the information collected for each patient would occur at initial contact, 
but there are many reasons why this may not happen in clinical practice.  Following 
the framework of other EHR-based studies (e.g. (Jordan et al. 2017; Rapsomaniki et 
al. 2014)), we used information recorded within a time window around the index date 
to generate baseline measurements.  We conducted a series of initial database 
searches to determine the best trade-off between the size of the time window and 
data completeness and determined that a window of one year prior to the index 
date, and 28 days after the index date was optimal for these patients. 
 
All adult patients (aged 16 years and above) who engaged with a SLaM CDATS on 
a face-to-face basis within the study timeframe were considered eligible for cohort 
inclusion.  We excluded those patients for whom no drug or alcohol use information 
was recorded within the baseline time window due to uncertainty regarding whether 
these patients were being treated for a SUD (approximately 1% of otherwise eligible 
patients).  No other exclusion criteria were applied. 
 
Risk Factors and Phenotype Algorithm Development 
 
We initially focused on extracting risk factor variables from the CRIS data as the data 
linkage process used to combine CRIS data with those from HES can only be 
conducted once.  When data linkage is complete, the BRC identification number 
used in CRIS is replaced with a new randomly generated ID, so no further data from 
CRIS can be added to the cohort.  Once the finalised CRIS data set was linked to 
relevant data from HES, a final round of data integration was completed for variables 




The CRIS system is complex as the ePJS is used by many different clinical services with 
different medical records needs.  Consequently, information relevant to the 
definition of a single variable may be recorded in multiple database tables and free-
text documents (e.g. clinical notes, referral letters).  To combine data from these 
sources in the most efficient way, we took a staged approach to variable definition.  
We first considered available structured data, and then considered use of natural 
language processing (NLP) data for variables where structured fields (e.g. diagnoses 
recorded using structured code systems such as ICD-10) did not yield sufficient data.  
For each variable, we used the following overall approach to identify the data 
available and how data from different sources could be integrated: 
 
1. Identify sources of structured information: Data sources were identified via 
discussions with clinical and informatics colleagues, and examination of 
database table structure. 
2. Examine content of each structured information source: Using a test cohort of 
patients meeting the basic inclusion criteria we examined how frequently the 
relevant database fields were populated with non-null values (within the 
cohort entry time window). 
3. Consider NLP data sources: For variables where structured fields were not well 
populated, we considered the use of NLP to extract data from clinical notes 
and other documents.  If relevant NLP algorithms for use with CRIS data already 
existed, we applied these to the test cohort to determine whether sufficient 
data could be extracted from available documents for this patient population.  
If no algorithm existed, the decision regarding whether to develop a de novo 
NLP algorithm was made based how frequently the relevant information was 
likely to be included in text documents and how critical the variable was to 
the planned analyses.  Further details of NLP approaches are provided in 
Appendix 1. 
4. Integrate structured and unstructured data: For those variable where data was 
extracted from more than one source, EHR phenotype algorithms were 
developed to define the strategy used to integrate and reconcile these data.  
 
The phenotype algorithms developed for extracting these data are a research 
output in their own right, but as the focus of this project is the data they are used to 
extract, details of the algorithms developed are only provided in Appendix 4 for the 




The SLaM BRC CRIS system has ethical and s251 approval.  Ethical approval is 
therefore not required for individual projects, but the CRIS Oversight Committee 
reviews all proposed research; Dr Morley received approval from the Committee for 




Standard descriptive statistics (mean, variance, percentages, counts) were used to 
summarise the risk factor information extracted from the medical record data. All 








This was a mixed-methods pilot study involving quantitative and optional qualitative 
interviews with SLaM Community Drug and Alcohol Treatment Services (CDATS) 
clients, and linkage of the quantitative interview data to medical records and 
national mortality data. It involved three components outlined below: a quantitative 
structured interview, a qualitative semi-structured interview, and permission for 
access to participants’ NHS records.   
 
In the structured interview, clients were asked about previous diagnoses with liver 
disease or related conditions, risk factors, and treatment for any diagnosed 
conditions.  The interview questionnaire includes the Alcohol Use Disorders 
Identification Test Alcohol Consumption questions (AUDIT-C) (Bush et al. 1998), Mini-
International Neuropsychiatric Interview (Sheehan et al. 1998), and items from the 
Treatment Outcomes Profile (TOP) (Marsden et al. 2008), the Blood Borne Virus 
Transmission Risk Assessment Questionnaire (Stoové et al. 2008), the HIV Risk-taking 
Behaviour Scale (Darke et al. 1991; Rash et al. 2016), and the Australian Needle and 
Syringe Program Survey (Wand et al. 2012).  Although participants could complete 
the questionnaire themselves, we have found that when working with this patient 
population, structured interviews result in better quality data (i.e. internally consistent, 
less missing data).  The structured interview form is provided in Appendix 2. 
 
Based on the quantitative interview, participants who reported being diagnosed with 
one of the following conditions and not receiving/seeking treatment were invited to 
discuss this further in a semi-structured interview: alcohol dependence, diabetes, 
hepatitis A, B, or C, HIV/AIDS, liver disease.  It was audio recorded and transcribed for 
analysis.  
 
Participants were asked for permission to link their quantitative interview data to their 
electronic medical record data held by SLaM, and to medical record data held in 
the Hospital Episode Statistics (HES) database, and to mortality data held by the 
Office of National Statistics (ONS), linked via NHS number.  
 
Participation in the qualitative interview and data linkage were optional (see Figure 
1 for detailed outline of procedures). All participants were reimbursed £20 for their 
time regardless of whether they consented to optional components to avoid 
coercion.  The reimbursement amount was determined in consultation with the SLaM 







Figure 1: Diagram of data management and linkage of participant data. Participants 
will be eligible to take part in the qualitative interview if they report being diagnosed 
with, but not treated for, the following conditions: alcohol dependence, diabetes, 
hepatitis A, B, or C, or liver disease.  Dashed lines indicate temporary links used to 
create final anonymised, linked, data set.  Audio recording (qualitative interview) 
data is not linked to other data, nor is the consent form.  All data collection items will 
be securely stored; those outlined in red will be securely destroyed at the conclusion 










As this was a pilot feasibility study that was not dependent upon the sample being 
representative, we used a convenience sample.  Participants were recruited from 
two SLaM Addiction Services clinics: Lambeth Drug and Alcohol Liaison and 
Assessment Service, and Wandsworth Drug and Alcohol Service. 
 
Before recruiting participants, the Chief Investigator attended staff meetings at each 
SLaM Addiction Services Clinic to present an overview of the study and request that 
clinic staff tell their clients about the study and how to contact research staff if they 
wish to be involved.  The research team then liaised with the managers from each 
clinic to identify the days/times when it would be most suitable for research staff to 
recruit clients from their clinic. 
 
Potential participants were identified and referred by clinical staff to the research 
team member present at the clinic, who determined whether clients are eligible for 
the study before proceeding further.  Clients were eligible for participation if they 
were currently receiving treatment for any substance use disorder, and were adults 
aged 16 years and over.  Clients were excluded if they had insufficient written and/or 
spoken English to provide informed consent and participate in the study, or were 





This study was given a favourable opinion by the East of England – Cambridge 
Central Research Ethics Committee (17/EE/0193) on the 5th of June 2017, and NHS 
Health Research Authority Approval on the 25th of July 2017.  South London and 
Maudsley NHS Trust Research and Development approval (R&D2017/063) was 




Questionnaire responses were double-entered into custom-designed databases and 
stored securely on a restricted-access server. Standard descriptive statistics (mean, 
variance, percentages, counts) were used to calculate the percentage of potential 
participants who agreed to participate in the study, and to summarise the risk factor 
information contained in the quantitative interview data. All analyses were 
conducted using the R Statistical Software.   
 
The aim of the qualitative analysis of interview transcripts is to identify patterns of 
meaning relating to barriers to treatment for liver disease and associated risk factors, 
some of which may not have been previously considered in the literature. Thematic 
analysis is currently underway. This method of qualitative analysis is designed to 
answer questions relating to people's experiences, or people's views and perceptions 
(Braun & Clarke 2014; Braun & Clarke 2006).  It is undertaken using iterative 
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categorisation, which permits the use of both deductive (coding and theme 
development directed by existing concepts or ideas) and inductive (coding and 
theme development directed by the content of the data) approaches (Neale 2016).  
Iterative categorisation does not require specialist software and can be conducted 




Study Design and Participant Recruitment 
 
Anonymous questionnaire surveys of clinical staff were administered in three SLaM 
CDATS.  The aim of this study was to investigate support for, and barriers to, treatment 
for liver disease and associated risk factors (viral infections, heavy alcohol 
consumption, safe sex and injecting practices) in addiction services. The 
questionnaire items were informed by:  
 
1. UK Department of Health guidelines on clinical management of drug misuse 
and dependence;  
2. NICE Clinical Guidelines for alcohol-use disorders, type-2 diabetes, hepatitis B;  
3. British HIV Association guidelines for treatment of HIV positive adults;  
4. Royal College of Physicians guidelines on management of hepatitis C. 
 
The full questionnaire can be found in Appendix 3 and includes collection of 
information on:  
 
1. resources for educating/treating clients for liver disease and associated risk 
factors;  
2. which conditions should be addressed during treatment;  
3. client interest in treatment;  
4. obstacles to treatment. 
 
Strategies for participant recruitment were devised via discussion with Clinical Leads 
at each site to minimise disruption to normal clinical practice and maximise 
participation.  Participants at two sites were recruited by a member of the research 
team presenting an overview of the study prior to a staff meeting and distributing the 
surveys to staff in attendance. Staff could return the questionnaire to the research 
team member at that time, or at another time of their choosing using a stamped 
envelope with the Chief Investigators postal address provided by the research team.  
At the third site, the Clinical Lead emailed the questionnaire to clinical staff who 
printed the forms and then either returned them to the Chief Investigator via post, or 
via email through the Clinical Lead.  All clinical staff were eligible to participate; there 
were no exclusion criteria. 
   
Ethical Approval 
 
The study was classified as a clinical audit and approved by the local SLaM NHS 






Questionnaire responses were double-entered into custom-designed databases and 
stored securely on a restricted-access server. Standard descriptive statistics (mean, 
variance, percentages, counts) were used to summarise the risk factor information 
extracted from the medical record data. All analyses were conducted using the R 













A total of 18,848 patients met our eligibility criteria.  The majority (70.0%) were male 
(see Table 1) and the average age was 39.7 years (standard deviation 11 years, 
minimum of 16 and maximum of 88).  Based on self-reported ethnicity, 76.4% were 
White, 13.2% Black, and 3.4% Asian.  Almost a third (28.2%) had an unstable housing 
situation.  It was not possible to extract any data on time spent in prison.   
 
Table 1: Sociodemographic characteristics of electronic health record data sample 
 
Category Value N Percent 
Gender Female 5652 30 
 Male 13195 70 
 Not Known 1 0 
Ethnicity Asian 634 3.4 
 Black 2492 13.2 
 Mixed 548 2.9 
 Other 521 2.8 
 Unknown 256 1.4 
 White 14397 76.4 
Housing status Stable 12979 68.9 
 Unknown 547 2.9 
 Unstable 5322 28.2 
 
Just over half the sample (51.9%) had a diagnosis of alcohol dependence or a record 
of problematic alcohol use.  Opiates were the most commonly used drug with 39.8% 
of the sample meeting our criteria for use.  The next most commonly used substance 
was cocaine or crack cocaine (35.6%), followed by cannabis (22.5%), methadone or 
buprenorphine (7.0%), and benzodiazepines (1.1%).   
 
Liver Disease and Clinical Risk factors 
 
A total of 751 patients (4% of total sample) had a liver disease diagnosis recorded at 
the time of CDATS contact.  Only 2% of patients had a diagnosis recorded for any 




Data on hepatitis A were insufficient to generate diagnoses.  For the majority of the 
sample, patient status for HIV, hepatitis B, and hepatitis C were missing (95.9%, 87%, 
and 83.9% respectively).  Where data were available, 30.0% were HIV positive, 6.6% 
were HBV positive, and 25.2% were HCV positive.   
 
Of the total sample, 65.4% had never injected drugs while 10.3% had previously 
injected and 13.6% reported currently injecting drugs.  Of those individuals who 
reported use of heroin and/or cocaine/crack, 24.7% reported currently injecting and 
17.2% reported injecting in the past.  Sharing equipment was not common; only 20.8% 
of patients who reported current or previous injecting also reported sharing 
equipment.  Only 5.1% of the cohort reported engaging in high-risk sexual behaviour, 
although this information was unknown for just over a quarter of patients. 
 
Following previous research using CRIS data (Chang et al. 2010), we defined the 
diagnosis of a serious mental illness (SMI) as a record of schizophrenia, schizoaffective 
disorders, or bipolar affective disorder.  Just over 7% of patients had a SMI diagnosis 
recorded, with the majority being a psychosis-related diagnosis (89.8%).  A diagnosis 






A total of 103 clients from two CDATS participated in the study.  Due to the fact that 
recruitment to the study occurred via a gatekeeper (clinical staff) the participation 
rate cannot be calculated, but 100% of clients who made contact with research staff 
agreed to participate.  Of these, 93% (n = 96) consented to linkage of their research 
questionnaire data to their electronic medical record data. 
 
Participants were predominantly male (78.6%), born in the UK (68%), and 
heterosexual (91.3%; see Table 2).  The majority (69%) had spent time in prison, 
although only 17.5% of the sample had done so in the past year.  A large proportion 
of participants were in rental accommodation (40.8%) or living with friends or relatives 
(15.5%), but many were homeless (28.2%; n = 29) or in unstable living situations (15.5%).   
 
Table 2: Sociodemographic characteristics of client survey sample 
 
Category Value N Percent 
Gender Female 22 21.4 
 Male 81 78.6 
Country of birth Non-UK 33 32 
 UK 70 68 
Sexual orientation Bisexual 5 4.9 
 Heterosexual 94 91.3 
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 Homosexual 4 3.9 
Time in prison No 32 31.1 
 Yes, but not in the past year 53 51.5 
 Yes, in past year 18 17.5 
Accommodation Hostel 6 5.8 
 Hotel or bed and breakfast 1 1 
 Living with friends/relatives 16 15.5 
 No fixed abode 29 28.2 
 Other 9 8.7 
 Rented (LHA) 29 28.2 
 Rented (private) 13 12.6 
 
Participants were predominantly receiving treatment for heroin use (68.9%; n = 71), 
but large proportions were receiving treatment for alcohol use (34%; n = 35), and 
crack cocaine use (30.1%; n = 31). 
 
Liver Disease and Associated Clinical Risk Factors 
 
A comparison of the percentage of clients with liver disease and associated risk 
factors in the self-report questionnaire data and EHR data described previously is 
shown in Table 3.  Note that missing data has a different meaning for EHR data as a 
diagnosis code is usually only recorded to indicate confirmation that a condition is 
present; a code is not generally recorded to indicate the absence of a condition.  
Thus data for most conditions will be missing for most patients by default and does 




Table 3: Comparison of results from electronic health record data and questionnaire 
data for clients 
 





(N = 18,848) 
Questionnaire data 
(N = 103) 
Liver disease Yes 4% 24.3% 
 No - 71% 
 Missing 96% 3.9% 
Hazardous alcohol use Yes 52% 56.3% 
 No - 43.7% 
 Missing 48% 0% 
Diabetes Yes 2% 3.9% 
 No 0% 95.1% 
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 Missing 98% 1% 
Hepatitis A Yes 0% 1% 
 No 0% 96% 
 Missing 100% 2% 
Hepatitis B Yes 1% 2% 
 No 12% 95% 
 Missing 87% 2% 
Hepatitis C Yes 4% 25% 
 No 12% 70% 
 Missing 84% 4% 
HIV/AIDS Yes 1% 4% 
 No 3% 95% 
 Missing 96% 1% 
Injecting drugs Currently 14% 20% 
 Previously 10% 29% 
 Never 65% 51% 
 Missing 11% 0% 
Sharing injecting equipment Not sharing 84% 82% 
 Sharing 5% 18% 
 Missing 11% 0% 
High-risk sexual behaviour Yes 5% 17% 
 No 69% 83% 
 Missing 26% 0% 
Serious mental illness Yes 7% 13% 
 No - 87% 
 Missing 93% 0% 
Anxiety and/or depression Yes 12% 66% 
 No - 34% 
 Missing 88% 0% 
 
For many conditions the results from the two samples are similar, but they differ for 
liver disease itself and some key risk factors.  Liver disease diagnoses were recorded 
for 4% of the EHR sample, but 24.3% of questionnaire participants reported a liver 
disease diagnosis.  This is similar to the results for hepatitis C; 4% of the EHR sample 
had a record of the condition, compared to 25% of the questionnaire sample.  
Questionnaire participants were also more likely to report having been diagnosed 
with mental health conditions, with 13% reporting a SMI (compared to 7% in the EHR 









Treatment for Liver Disease and Associated Risk Factors 
 
In the majority of cases, clients who had been diagnosed with liver disease or 
associated risk factors reported receiving treatment.  Of the 25 participants who 
reported a liver disease diagnosis, 32% had received treatment and 20% had not (the 
remainder were unsure).  The percentages receiving treatment for risk factors were: 
76% for alcohol dependence, 100% for diabetes, 100% for hepatitis A, 50% for 
hepatitis B, 58% for hepatitis C, and 75% for HIV/AIDS.  Note that the percentages for 
diabetes, hepatitis B and C and based on small diagnosis numbers (4, 2 and 4 
participants respectively).   
 
Patients who had not received treatment were invited to participate in a semi-
structured qualitative interview to explore this further.  Analysis of these data is 
ongoing but preliminary results suggest that: (i) patients not receiving treatment for 
alcohol dependence is due to patient refusal rather than lack of clinical support; (ii) 
lack of treatment for hepatitis C and liver disease is due to difficulties in accessing 
treatment via the NHS, particularly long waiting times, rather than lack of support 






A total of 50 clinical staff from three sites participated in the survey.  Participation 
rates for the two sites where data were physically collected were 69% and 100%.  The 
participation rate for the site where data where questionnaires were distributed 
electronically is unknown.  The sample was 56% female with an average age of 43.4 
years (s.d. = 9.4 years).  On average, participants had 11.6 years of clinical 
experience (s.d. = 7.5 years).  Participants were mainly Drug Recovery Workers (38%) 
or Registered Nurses (26%), with the remaining participants including Psychologists, 
Psychiatrists, and Support Staff. 
 
Resources and Training for Addressing Liver Disease Risk Factors 
 
The majority of participants felt they had access to sufficient access to resources to 
support for clients in regard to alcohol dependence (84%), hepatitis B (86%), hepatitis 
C (86%), HIV (82%), safe sex practices (78%), and needle exchange (92%).  Fewer 
participants felt there were adequate resources for addressing liver disease, with only 
66% reporting sufficient resources, 18% reporting insufficient resources, and 16% 
unsure or not responding to the question.  Just over a quarter of the sample (28%) 
had participated in further training regarding liver disease, but 56% reported that 









Addressing Risk Factors During Alcohol/Drug Treatment 
 
Participants reported that alcohol use, liver disease, HIV/AIDS, and hepatitis C were 
all considered a high priority for addressing during alcohol/drug treatment (Figure 2).  
However, responses were more mixed for diabetes, and hepatitis A and B. 
 
 
Figure 2: Staff priority for addressing liver disease and associated risk factors during 
alcohol/drug treatment 
 
Perception of client interest in addressing these factors during treatment was similar 
to staff importance (see Figure 3), although the results suggest that clients view liver 
disease as less of a priority than clinical staff. 
 
 
Figure 3: Perceived client interest in addressing liver disease and associated risk 











Obstacles to Treatment for Liver Disease and Associated Risk Factors 
 
Participants viewed the biggest obstacles to treatment for liver disease and 
associated risk factors for clients as their low personal health priorities (72%), their 
underappreciation of the health consequences of heavy alcohol use (68%), and 
their lack of understanding of viral hepatitis and its health consequences (62%).  
Practical difficulties and fear of stigma or discrimination were less likely to be viewed 
as obstacles (52% and 46% respectively).   
 
From a clinical perspective, the three most frequently endorsed obstacles to 
treatment were: clients failing to engage with treatment (80%), clients’ unstable living 
arrangements (70%), and client mental health (60%).  Uncertainty over duty of care 







Presence of Liver Disease and Associated Risk Factors 
 
Overall there were substantial percentages of CDATS patients with one or more risk 
factors for liver disease, many of which are modifiable.  Over half of patients have a 
record of engaging in hazardous alcohol use, and approximately a quarter have 
injected drugs, with a similar percentage having hepatitis C.   
 




The percentage of patients with a diagnosis of liver disease varied substantially 
between the two CDATS patient samples; 4% of the EHR sample were diagnosed with 
liver disease compared to 24% of the questionnaire sample.  There are multiple 
possible reasons for this.  The first is the definition of liver disease.  For the EHR data we 
focused on serious liver conditions i.e. Stage 2 (fibrosis, cirrhosis, hepatocellular 
carcinoma etc.) and Stage 3 (liver failure).  However, most of the patients 
interviewed were unsure about the type of liver disease they had been diagnosed 
with, and it is likely that many of them had been diagnosed with Stage 1 conditions 
such as alcoholic liver disease.  Second, patients may have been warned that their 
alcohol use and/or hepatitis C infection was having an impact on their liver function, 
and confused this receiving a formal diagnosis of liver disease.  Third, the EHR data is 
limited in terms of timeframe and location, and patients may have referenced 
diagnoses that occurred outside our timeframe, or outside the NHS (England) system. 
 
Sociodemographic Risk Factors 
 
A large proportion of both samples were in unstable housing; 28.2% of the EHR sample 
and 43.7% of the questionnaire sample.  The difference between the two samples 
may be due to bias in the sampling strategy and reimbursement for the questionnaire 
sample. Recruitment had to occur via a gatekeeper, so we do not know who refused 
contact with the research time; those in unstable housing situations may have been 
more likely to participate due to the participant payment offered.  However, most 
clients interviewed were unaware they would be compensated for their time until it 
was explained to them as part of the consent process.  A comparison of country of 
birth and time in prison between the EHR and questionnaire samples was not possible 
as this information was not accessible from the EHR database. 
 
Clinical Risk Factors 
 
The percentages of participants with clinical risk factors for liver disease were similar 
between the EHR and questionnaire samples for the majority of factors, but there 
were striking differences for hepatitis C and mental health conditions.  For hepatitis 
C, 4% of the EHR sample had a record of the condition, compared to 25% of the 
questionnaire sample.  However, this difference is primarily due to how blood test 
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results are recorded in ePJS.  Blood test results are returned to clinical staff as an 
image file, rather than a text file, and these are not currently accessible via the 
research EHR interface (CRIS).  Although there are text-based ePJS fields that blood 
test results can be entered into (and thus accessed for research), in practice, given 
the time-pressures faced by clinical staff, this is rarely done as from the clinic-facing 
side of the system this would be an unnecessary duplication of information.   
 
There was also a substantial difference in the percentage of participants reporting 
anxiety and/or depression diagnoses.  This was reported by 66% of the questionnaire 
sample, but diagnoses were only recorded for 12% of the EHR sample.  One partial 
explanation may be that some participants were reporting on having feelings of 
anxiety or depression, rather than receiving clinical diagnosis, although 78% of those 
who reported depression also reported receiving clinical treatment (e.g. cognitive 
behavioural therapy and/or antidepressant medication).  The major cause of the 
difference is likely to be the absence of primary care data for the SLaM EHR resource, 
as many of these diagnoses and associated treatment are likely to have been made 
by a GP.  Linkage between the GP databases for the SLaM catchment is underway, 
but not yet complete. 
 
Attitudes to Interventions for Risk Factors for Liver Disease 
 
Clinical perspectives on patient obstacles to treatment for liver disease risk factors 
related to low client priorities regarding overall health and lack of understanding 
about the consequences of viral infections and alcohol use, with the consequence 
that clients did not engage with specialist treatment.  This suggests a possible role for 
tools focused on improving risk communication and patient education, and thus 
increasing treatment interest and uptake. 
 
However, staff also highlighted unstable living situations and poor mental health as 
obstacles to treatment for liver disease risk factors.  This is particularly concerning 
given the large percentage of patients who reported unstable living situations 
(approximately 30-40%), and mental health problems (between 10 and 65%).  This 
suggests that supporting clients to organise stable housing and access mental health 
treatment (either medication or psychological therapy) may also indirectly improve 
treatment of liver disease risk factors. 
 
Assessment of Pilot Study 
 
In practical terms, the original objectives of this study were to:  
 
(i) extract and analyse EHR data on liver disease risk factors from SLaM CDATS 
clients;  
(ii) collect and analyse questionnaire data from 250 SLaM CDATS clients;  
(iii) link and analyse questionnaire data from SLaM CDATS clients to their EHR 
data;  





Objectives (i) and (ii) were successfully completed.  Objective (iii) was only partially 
completed, in that only 103 clients were recruited.  This was due to a number of 
factors.  First, the SLaM Service User Research Group that we discussed the project 
with advised on increasing our proposed participant reimbursement from £15 to £20, 
which reduced the number of participants we could recruit with available funds to 
200.  Second, ethical and regulatory approvals took eight months, which was 
approximately double the time anticipated based on previous applications.  Third, in 
consequence of the delay two members of the research team (one 100% FTE, one 
60% FTE) who were planning to undertake data collection left the project before 
data collection started (one took parental leave, and the other was awarded a 
travel fellowship).   
 
This problem was partially solved by employing two casual Research Assistants to 
help the Principle Investigator undertake data collection (using discretionary funds 
held by the Principle Investigator).  We were able to recruit 103 participants with only 
15 days of data collection; were more time and more funds for staff available, we 
would have reached our revised goal of 200 participants.  Due to the delayed start 
of data collection, we have not completed objective (iv), but linkage will be 
completed within the next two months. 
 
Overall, the pilot of this study has been successful in developing a viable study 
protocol, and demonstrating the feasibility of recruiting CDATS patients.  It has also 
demonstrated the acceptability of linking self-reported questionnaire data to EHR 




The immediate next steps for this research are to complete the data linkage and 
analyses and prepare the results for publication in a scientific journal.  Once 
published, this article will be sent to Alcohol Research UK. 
 
The medium-term next steps relate to both funding and further research.  The results 
of this study, and the protocol itself, will form the basis of a grant application to 
undertake this research on a larger scale and in different patient populations in which 
understanding alcohol and drug use is clinically important (e.g. in emergency 
psychiatric care admissions).  The data set linking client self-report questionnaire and 
medical record data will also be valuable for the further development of algorithms 
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Two Information Extraction (IE) tools are currently available for use with CRIS: 
TextHunter and SemEHR.  TextHunter has been used over a number of years to 
develop applications for extracting information on a range of psychiatric diagnoses 
and symptoms, as well as substance use and physical health conditions (for summary 
see (Perera et al. 2016).  Output from existing TextHunter applications was used in the 
development of some variables, but as no new applications were developed for this 
cohort we do not describe TextHunter in detail here.  Full details can be found in 
(Jackson et al. 2014). 
 
The SemEHR IE tool has only recently become available for use with CRIS data.  We 
used it to develop applications for extracting data on hepatitis C virus (HCV) infection 
and diagnosis of liver disease (LD).  Briefly, SemEHR uses a NLP pipeline dedicated to 
annotating UMLS (Unified Medical Language System) concepts to identify mentions 
of a wide range of biomedical concepts in clinical notes, including terms from 
SNOMED CT, ICD-10, LOINC, and Drug Ontology. Each concept mention is also 
associated with 4-dimensional context information - negated, historical, hypothetical 
and experiencer. A patient-centric data model is then constructed to represent and 
associate three types of entities - Patient, Concept Mention and Clinical Note. Based 
on the model, a semantic search index is constructed to realise google-style 
searching for all entities and their associations. Most importantly, SemEHR 
incorporates semantic associations (from biomedical ontologies) between concepts 
(e.g. Steatohepatitis is a liver condition; Ribavirin is a drug for treating Hepatitis C), 
which are utilised in all types of searches SemEHR provides.  Full details are available 
in (Wu et al. 2018). 
 
Development of Patient-level Classifiers 
 
The IE applications developed for this project recognise and classify individual 
mentions of a concept in available text, but do not produce an assessment at 
patient level.  For example, a patient who is HCV positive is likely to have many 
mentions of HCV-related concepts in her clinical notes.  However, not all of these 
mentions will necessarily indicate that the patient is HCV positive; some may refer to 
previous negative test results, or the HCV status of a relative or partner.  The user must 
then develop a strategy for using the collection of results to produce an assessment 
at patient level. For each phenotype for which IE application data were available, 



































APPEAL FOR STAFF OPINIONS ON AVAILABLE NHS RESOURCES FOR TREATMENT OF 






1. Please select the professional group you are from (tick only one box) 
 
Admin and support Assistant Psychologist Consultant Clinical Psychologist 
Training Grade Doctor Trainee Psychologist	 Consultant 
Psychiatrist/Physician	 
Non-training Grade Doctor Social worker	 Occupational Therapist	 




3. Have you been given opportunities for further or specialist training about liver disease?  
(please tick only one box) 
Yes, I have taken part in a training course 
Yes, but I have not had the time to take part yet 
Yes, but I have not taken part as it is not relevant to my role 
Yes, but I have not taken part as the training required out of pocket expenses 
No, I have not been given an opportunity for training about liver disease 
Other (please specify):_________________________________________________________ 
4. Which, if any, of these conditions do you feel it is important to address during drug and alcohol treatment? 
(please tick as appropriate) 
 




Alcohol consumption in 
drug-dependent clients 
    
Diabetes     
Hepatitis A     
Hepatitis B     
Hepatitis C     
HIV     
Liver disease     
2. Do you feel adequate resources are available in order to educate service users or provide services for the 
following? (please tick as appropriate) 
 Yes No Don’t know 
Alcohol consumption (in drug-dependent clients)    
Hepatitis B    
Hepatitis C    
HIV    
Safer-sex practices    
Syringe exchange service    
Liver disease    
Age (years):  Gender:											Male															Female	
 
Clinic:_________________ 









6. What do you think are the biggest obstacles in the treatment of liver disease and associated risk factors 
from a service user perspective? (tick all that apply) 
	
Clients’ low priority to personal health problems	 Practical difficulties in attending specialist 
clinics	
Clients’ lack of understanding of hepatitis and its 
associated health consequences	
Fear of stigma/discrimination in primary care 
and/or specialist clinics	
Clients’ underappreciation of the health 
consequences of heavy alcohol consumption	 Other (please specify):__________________	
 
 
8. What do you think are the percentages of clients who are vaccinated against hepatitis A and B in your 
service? (please tick as appropriate)	
  0-20%  21-40%  41-60%  61-80%  81-100% Not sure 
Hepatitis A            
Hepatitis B            
Hepatitis A and B            
 
	
11. Do you have any further comments about the treatment of liver disease and liver disease risk factors? 
(please use the space provided) 
5. How interested do you think service users are in addressing the following conditions? 





Not interested Don’t know 
Alcohol consumption in 
drug-dependent clients 
    
Diabetes     
Hepatitis A     
Hepatitis B     
Hepatitis C     
HIV     
Liver disease     
7. What do you think are the most important obstacles to treatment of liver disease and risk factors from a clinical 
perspective? (tick all that apply) 
 
Service users refusing, or failing to turn up for, 
specialist referral appointments 
Lack of liver doctors providing outreach clinics or 
scanning facilities in drug and alcohol services 
Homelessness or unstable living arrangements in 
service users 
Uncertainty about duty of care between drug and 
alcohol services and primary care 
Mental health problems in service users Lack of abstinence from alcohol/drugs in service 
users 
Other (please specify):  
__________________________________________ 
 
9. What do you think is the percentage of clients who are aware of hepatitis B and C treatments in your clinic?  
 
0-20% 21-40% 41-60% 61-80% 81-100% Not sure 
10. The Addictions Department at King’s College London conducts research within SLaM drug and alcohol 
services on a regular basis. Have you been part of or involved in the recent PRAISe study? 
 








Gender and ethnicity were readily available and required no further processing. Age 
at first face-to-face contact was computed using the cleaned date of birth (year 
and month of birth, but not the day).  Whether a patient has previously spent time in 
prison is not routinely recorded in any structured fields.  Patient living situation and 
employment status involved the integration of structured data from multiple sources.  
Patients were considered to be in an unstable living situation if there were data in the 
structured record reporting: participant housing status as homeless or unstable; a 
housing problem; or urgent need for accommodation.  Patients with no records 
indicating an unstable living situation and a report confirming a stable living situation 
or no housing problem were categorised as being in a stable living situation.  All other 
patients were treated as having missing data.   
 
Alcohol and Drug Use 
 
Information on substance was available from a wide range of sources and covers a 
broad range of substances, but we focused on those illicit drugs that are reported 
relatively frequently in these clients (Simonavicius et al. 2018) namely: opiates 
(including opioid analgesics), cocaine (including crack cocaine), and cannabis.  We 
also included methadone and buprenorphine use, and benzodiazepine use.  For 
alcohol and illicit drugs there were multiple sources of information that included ICD-








Alcohol  Alcohol F10* 
Opiate  
 
Heroin, Other Opiates, Dihydrocodeine, 




Cocaine, Cocaine Hydrochloride, Crack 
Cocaine F14* 





Benzodiazepam Benzodiazepam, Diazepam, Alprazolam  
 
We treated the recording of an ICD-10 diagnosis relating to a substance, or listing of 







As few diagnoses of liver disease were identified based on structured fields in CRIS, 
we developed an IE tool for clinical notes using SemEHR.  We used terms relating to 
liver diseases that could be at least partially causes by alcohol and/or drug abuse, 
with the exception of viral hepatitis as this would have created an overlap with the 
hepatitis C tool.  As the tool only provided one source of information (presence or 
absence of a relevant term), a simple rule-based phenotype was used with the 
presence of at least one term considered sufficient for a diagnosis.  We combined 
this information with liver disease diagnoses recorded using ICD-10 codes in HES data: 
K70.2, K70.3, K70.4, K71.7, K72.1, K72.9, K74.0, K74.1, K74.2, K74.6, K76.6. 
   
Mental Health 
 
Following previous research using CRIS data (Chang et al. 2010), we defined the 
diagnosis of a serious mental illness (SMI) as a record of schizophrenia, schizoaffective 
disorders, or bipolar affective disorder during the time window.  Data were extracted 
as ICD-10 codes from the CRIS Diagnosis table and HES inpatient and outpatient 
diagnoses (F20, F25, and F31 respectively), and via keyword searches of the Diagnosis 
IE tool output.  We defined the diagnosis of anxiety and/or depression as a record of 
depressive episode, recurrent depressive disorder, phobic anxiety disorders, or other 
anxiety disorders.  ICD-10 codes F32, F33, F40, and F41 were used respectively, in 




We applied an existing IE application for diabetes as no diabetes diagnoses were 
recorded in structured fields, but CRIS records contained insufficient information to 
generate diagnoses.  Thus only diagnoses from HES, using ICD-10 codes, were 




Information on injecting drug use and sexual-risk taking is not well-recorded in HES, so 
this information was only drawn from CRIS using assessment forms specifically 
designed for addiction services: Treatment Outcomes Profile (Marsden et al. 2008), 




As few diagnoses of hepatitis C were identified based on structured fields in CRIS, we 
developed an IE tool for clinical notes using SemEHR.  We used terms relating to 
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diagnosis of hepatitis C, and also terms for drug combinations used primarily for 
treatment of hepatitis C.  For more information see (Wu et al. 2018).  For HIV/AIDS we 
used an existing TextHunter IE tool which focused on HIV/AIDS diagnoses and 
medication used to treat the condition.  The output for the IE tools was combined 
with relevant ICD-10 codes recorded in HES data: B15*, B16*, B17.0, B17.1, B18.0, 
B18.1, B18.2, B20*, B21*, B22*, B23*, B24*.  
 
